Tight glycaemic control and cardiovascular disease in type 2 diabetes

Demssie, Yared N.; Soran, Handrean; Younis, Naveed
January 2009
British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p31
Academic Journal
The role of tight glycaemic control in reducing cardiovascular events and mortality in type 2 diabetes has not yet been firmly established. Recent clinical trials have yielded unexpected outcomes. This review summarizes the background and outcome of these trials and the implications for management of glycaemia in type 2 diabetes.


Related Articles

  • Study protocol--metabolic syndrome, vitamin D and bone status in South Asian women living in Auckland, New Zealand: a randomised, placebo-controlled, double-blind vitamin D intervention. von Hurst, Pamela R.; Stonehouse, Welma; Matthys, Christophe; Conlon, Cathryn; Kruger, Marlena C.; Coad, Jane // BMC Public Health;2008, Vol. 8 Issue 1, p267 

    Background: The identification of the vitamin D receptor in the endocrine pancreas suggests a role for vitamin D in insulin secretion. There is also some limited evidence that vitamin D influences insulin resistance, and thus the early stages of the development of type 2 diabetes. Methods:...

  • Radiation-modified albumin in type 2 diabetic patients. Kalnina, Inta; Kirilova, Elena; Zvagule, Tija; Kurjane, Natalija; Skesters, Andrejs; Silova, Alise; Gabruseva, Natalija; Gorbenko, Galina; Kirilov, Georgii; Gonta, Svetlana // Journal of Experimental & Integrative Medicine;2013, Vol. 3 Issue 1, p3 

    Objectives: Diabetes mellitus has been one of the most crippling diseases that man has seen, and its prevalence has risen dramatically over the past two decades. Currently, there are over 150 million diabetics worldwide and this number is likely to increase to 300 million or more by the year...

  • Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Van Zuilen, Arjan D.; Van der Tweel, Ingeborgh; Blankestijn, Peter J.; Bots, Michiel L.; Van Buren, Marjolijn; Ten Dam, Marc A. G. J.; Kaasjager, Karin A. H.; Van de Ven, Peter J. G.; Vervoort, Gerald; Vleming, Louis-Jean; Ligtenberg, Gerry; Wetzels, Jack F. M. // Trials;2006, Vol. 7, p8 

    Background: Patients with chronic kidney disease (CKD) are at a greatly increased risk of developing cardiovascular disease. Recently developed guidelines address multiple risk factors and life-style interventions. However, in current practice few patients reach their targets. A multifactorial...

  • Type II diabetes trial appears feasible: enrollment planned.  // Geriatrics;Feb1993, Vol. 48 Issue 2, p27 

    This article presents information about a randomized multicenter clinical trial of adult-onset diabetes which is planned to begin in June 1993. According to study chairman Carlos Abraira, MD, professor of medicine, Loyola University, Chicago, the study's purpose is to determine if physicians can...

  • Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Derosa, Giuseppe; Salvadeo, Sibilla Anna Teresa // Core Evidence;2007, Vol. 2 Issue 3, p189 

    Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone...

  • Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Matza, Louis S.; Boye, Kristina S.; Yurgin, Nicole // Health & Quality of Life Outcomes;2007, Vol. 5, p47 

    Background: Prior to using a generic patient-reported outcome measure (PRO), the measure should be validated within the target population. The purpose of the current study was to validate two generic measures in patients with type 2 diabetes. Methods: Patients with type 2 diabetes in Scotland...

  • Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function. Siekmeier, Rüdiger; Grammer, Tanja; März, Winfried // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2008, Vol. 13 Issue 4, p279 

    The article discusses clinical studies made on the effects of reactive oxygen species (ROS), nitric oxide (NO) and asymmetric dimethylarginine (ADMA) in treating endothelial dysfunction which causes atherosclerotic vascular diseases. Studies show that the use of the mentioned agents alone cannot...

  • Impaired Fasting Glucose: How Low Should It Go? Shaw, Jonathan E.; Zimmet, Paul Z.; Hodge, Allison M.; Courten, Maximilian De; Dowse, Gary K.; Chitson, Pierrot; Tuomilehto, Jaakko; Alberti, K. George M. M. // Diabetes Care;Jan2000, Vol. 23 Issue 1, p34 

    Impaired fasting glucose (IFG) has been recently introduced as a stage of abnormal carbohydrate metabolism, but the evidence on which its glucose limits are based is not strong. The aim of this article was to determine if the glucose limit represents a clear cutoff in terms of the risk of future...

  • Fenofibrate cuts CV event in diabetes patients.  // Pulse;11/19/2005, Vol. 65 Issue 45, p13 

    The article reports that finofibrate appears to reduce total cardiovascular events in patient with type 2 diabetes as concluded by large-scale prevention trial.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics